Skip to content
Apply
Stories

The J&J rescue mission starts with a choice

People in this story

The Atlantic, May 2021

Had Johnson & Johnson’s COVID-19 vaccine been the first to get the FDA’s green light, it might have been hailed from the get-go for what it actually is: a scientific and technological marvel. It requires just one injection to confer full immunity—a boon for needlephobes and tough-to-reach populations who can’t easily access a second dose. It’s relatively cheap and has forgiving refrigeration requirements, making it a breeze to ship and store. And clinical trials showed that it’s a knockout at guarding against hospitalization and death, and 66 percent effective at preventing moderate to severe cases of COVID-19, even amid the rise of antibody-dodging coronavirus variants. Johnson & Johnson accomplished all this in less than a year, granting the world a safe and effective vaccine crucial to hastening the pandemic’s eventual end.

That’s not how the J&J story played out.

Continue reading at The Atlantic.

More Stories

Policeman stops woman driver to give her a traffic ticket for speeding. He takes her driver's license.

Massachusetts police pull over more minorities than whites, new data shows

11.30.2023
Political cartoon of politicians paying to People of Color in 2020 during election season, then ignoring their commitments in 2023.

Large Massachusetts companies need to do better

11.29.2023
Taylor Swift singing at one of her

Another Taylor Swift course is coming to Boston, this time at Northeastern University

11.30.23
In the News